All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View GvHD content recommended for you

EHA 2022

Share:

Jul 1, 2022

X post image

8 Aug 2022

At #EHA2022, updated results of two trials studying Orca-T were presented. Overall survival was 90% with use of Orca-T compared with 68% in a historical control cohort. Read more here 👇 #GvHD
https://t.co/Khgvrzxk7I

X post image

7 Jul 2022

📹 During #EHA2022, the GvHD Hub spoke with @nagler_EBMT, @TelAvivUni. We asked, How do you optimize donor selection for allogeneic transplant? Comparing MSD, UD, and haploidentical donors

👉 https://t.co/ODlQkqHm8K 👈

#GvHD

X post image

6 Jul 2022

🍎 Will the preliminary results of this phase III prospective trial on non-restrictive diet post-HSCT change practice? Read a summary of Stella’s presentation from #EHA2022 here:

👉 https://t.co/DBbft3ROUV 👈

#GvHD #GvHDsm @LaStatale

X post image

1 Jul 2022

🎥During #EHA2022, the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg. We asked, What is the role of human beta-defensin-2 (HBD-2) in modulation of the microbiome and acute #GvHD (aGvHD)❓
Watch here 👇
https://t.co/MT2RZD4E4r

X post image

21 Jun 2022

Check out our twitter moment from #EHA2022, which includes all our updates from the congress 👀👇

https://t.co/685M5MnwPT

X post image

20 Jun 2022

CONGRESS #EHA2022 | Tamina Rückert @Uniklinik_Fr describes work on a human β‑defensin 2 peptide in GI #gvhd in mice & humans. HBD-2 reduced aGvHD severity. The microbiome showed increased bacteriodes species & there was reduced infiltration of immune cells in the ileum #gvhdsm

X post image

20 Jun 2022

CONGRESS #EHA2022 | @nagler_EBMT @TelAvivUni reports on MSD vs UD vs haplo donors for allo-HSCT in pts reaching 1st CR after 2 x induction. Higher incidence of aGvHD II-IV with UD 10/10; UD 9/10 & haplo vs MSD. Higher incidence of cGvHD & lower GRFS with UD 9/10 vs MSD. #gvhdsm

X post image

20 Jun 2022

CONGRESS #EHA2022 | Caspian Oliai @UCLAHealth discusses the results of a phase Ib/II study of ORCA-T for #gvhd prophylaxis N=138. cGvHD at 1 year was 5% with Orca-T vs 38% with CIBMTR comparator and relapse was 20% vs 35%, respectively. A phase III study is enrolling #gvhdsm

X post image

12 Jun 2022

We hope you’ve enjoyed keeping up with our live #EHA2022 congress updates! 🎓

Keep an eye on our socials for post-congress summaries and key insights! 📲

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

CONGRESS | #EHA2022 | Ruihao Huang, Xinqiao Hospital gives a talk on a trial investigating MSC infusion for GvHD prophylaxis in haplo-HSCT. Significant improvement in GRFS (65.6% vs 43.7% in control group). #gvhd

X post image

12 Jun 2022

CONGRESS | #EHA2022 | Federico Stella, @LaStatale presents results from a multi-center NEUTRODIET study comparing protective diet and non-restrictive diet.
- No difference in infection rates, death or aGvHD incidence
- Higher GI rates with protective diet
#gvhd

X post image

12 Jun 2022

CONGRESS | #EHA2022 | Simone Dertschnig, Priothera SAS, presents the first-in-human results from S1P receptor mocravimod in patients undergoing allo-HSCT. Mocravimod was well-tolerated and survival data were encouraging. #gvhd

X post image

12 Jun 2022

Its the final day of the 2022 @EHA_Hematology congress! Stay tuned for live coverage of the following sessions:

Clinical studies in transplantation

#EHA2022 #medicalcongress #cancerawareness

X post image

11 Jun 2022

Keep an eye on our Twitter page!
The GvHD Hub will be bringing you live updates as we continue our live coverage of @EHA_Hematology congress!
Session covered today:
- Stem cell transplantation and gene therapy - Experimental
#EHA2022 #medicalcongress #cancerawareness

X post image

10 Jun 2022

The GVHD Hub will be covering the following session/s today virtually (&/or) in-person:

Stem cells and their niche

Stay tuned for live updates, key insights, and interview coverage!

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

EARLY INFUSION OF MSCS IN THE PROPHYLAXIS OF GVHD AFTER HAPLO-HEMATOPOIETIC STEM-CELL TRANSPLANTATION

#EHA2022 #GvHDsm #GvHD

X post image

7 Jun 2022

NON-RESTRICTIVE DIET DOES NOT INCREASE GASTROINTESTINAL INFECTIONS AND FEBRILE NEUTROPENIA IN PATIENTS WITH NEUTROPENIA AFTER STEM CELL

#EHA2022 #GvHDsm #GvHD

X post image

7 Jun 2022

MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

#EHA2022 #GvHDsm #GvHD

X post image

7 Jun 2022

🚨 #EHA2022 Hot topics 🚨

See the thread below for recommendations from the GvHD steering committee for EHA2022👇

HUMAN ΒETA-DEFENSIN 2 TREATMENT MODULATES THE INTESTINAL MICROBIOME AND THE ALLOGENEIC T CELL RESPONSE TO LIMIT ACUTE GRAFT-VERSUS-HOST DISEASE

#GvHDsm #GvHD

X post image

7 Jun 2022

The @gvhd_hub will be covering the EHA 2022 Congress!

The first ever hybrid @EHA_Hematology congress, where we will be attending online and in Vienna!

Keep an eye on our socials for live updates throughout the day! 🗣💻

#EHA2022 #medicalcongress #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022 European Hematology Association

Newsletter

Subscribe to get the best content delivered to your inbox